Genentech is continuing its summer of downsizing and cost-cutting, this time with plans to terminate a cell therapy deal worth as much as $2 billion.\u00a0<\/p>\n
The pact is with Adaptive Biotechnologies and originally launched in January 2019. The deal was designed to help Genentech develop personalized cancer medicines based on Adaptive\u2019s T-cell receptor (TCR) tech.<\/p>\n
The cancellation of the collaboration and licensing agreement will be final on Feb. 9, 2026, according to an Aug. 18 filing<\/a> with the Securities and Exchange Commission.<\/p>\n \u201cWe highly value Adaptive as an innovative company and partner, and recognize the efforts that both partners have contributed to this collaboration over the last six and half years,\u201d a Genentech spokesperson told Fierce in a statement. \u201cLike any decision to end a collaboration, we have taken the utmost care and thoughtful consideration. This decision was not based on any emerging safety concerns.”<\/p>\n Adaptive received $300 million upfront<\/a> from the deal, with more than $2 billion in milestones originally on the table as well. The Seattle-based biotech\u2019s TruTCR technology is designed to identify T-cell receptors that recognize the unique antigens of a patient\u2019s cancer so that personal therapies can be developed.<\/p>\n \u201cAdaptive appreciates Genentech\u2019s partnership throughout this valuable collaboration. We remain committed to advancing TCR discovery with our digital TCR-antigen prediction model,\u201d an Adaptive spokesperson told Fierce in a statement. \u201cThis model could power other novel immunology applications and partnering opportunities. We are also continuing to build out a T-cell depletion program in autoimmunity.\u201d<\/p>\n Genentech\u2019s reneging mirrors a similar deal termination from April 2024 when the Roche company walked away from a cell therapy pact<\/a> with Adaptimmune worth up to $3 billion. That decision came the same week Genentech cut 3% of its workforce. Several months later, the Bay Area outfit announced a broad rethink<\/a> of its R&D operations, scrapping its cancer immunology research department.<\/p>\n After a spring of <\/a>deal-making<\/a>, Genentech has held two rounds<\/a> of layoffs<\/a> this summer\u2014one in June<\/a> and another in July\u2014<\/a>and walked away<\/a> from an oncology R&D pact with Bicycle Therapeutics about a month ago.<\/p>\n","protected":false},"excerpt":{"rendered":"Genentech is continuing its summer of downsizing and cost-cutting, this time with plans to terminate a cell therapy…\n","protected":false},"author":2,"featured_media":81876,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[42254,1115,12822,41960,3772,41974,9275,1360,41515,9035,134],"class_list":["post-81875","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-adaptive-biotechnologies","tag-biotech","tag-cancer-drugs","tag-cell-gene-therapy","tag-deals","tag-development-deals","tag-fierce-biotech-homepage","tag-genentech","tag-licensing-deals","tag-personalized-medicine","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116733735426633345","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/81875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=81875"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/81875\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/81876"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=81875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=81875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=81875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}